Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia
Stopped The study was prematurely terminated on 14th March 2023 for strategic considerations due to the limited efficacy seen with this treatment in monotherapy. This decision was not based on any safety concerns.
Conditions
- Relapsed or Refractory Acute Myeloid Leukemia
- Relapsed or Refractory Non-Hodgkin Lymphoma
- Relapsed or Refractory Multiple Myeloma
- Relapsed or Refractory Chronic Lymphocytic Leukemia
Interventions
- DRUG: S65487- initial scheme
- DRUG: S65487 - alternative scheme
Sponsor
Institut de Recherches Internationales Servier
Collaborators